CN103833623B - 一种氨基酸-胺缀合物及其制备方法和应用 - Google Patents
一种氨基酸-胺缀合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN103833623B CN103833623B CN201410074636.0A CN201410074636A CN103833623B CN 103833623 B CN103833623 B CN 103833623B CN 201410074636 A CN201410074636 A CN 201410074636A CN 103833623 B CN103833623 B CN 103833623B
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- aminoacid
- amine conjugate
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 title claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 77
- 235000001014 amino acid Nutrition 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000000118 anti-neoplastic effect Effects 0.000 claims abstract description 8
- 230000008685 targeting Effects 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims abstract description 7
- 238000006243 chemical reaction Methods 0.000 claims description 51
- 239000007787 solid Substances 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical group CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
- 230000006837 decompression Effects 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 11
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 10
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 10
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 8
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 8
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 claims description 8
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 claims description 8
- 229960004756 ethanol Drugs 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- 238000001953 recrystallisation Methods 0.000 claims description 6
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 229930195733 hydrocarbon Natural products 0.000 claims description 4
- 150000002430 hydrocarbons Chemical class 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 2
- -1 amino-acid compound Chemical class 0.000 claims description 2
- 238000004821 distillation Methods 0.000 claims description 2
- BYXYCUABYHCYLY-UHFFFAOYSA-N isoindole-1,3-dione;potassium Chemical compound [K].C1=CC=C2C(=O)NC(=O)C2=C1 BYXYCUABYHCYLY-UHFFFAOYSA-N 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 239000002904 solvent Substances 0.000 description 22
- 238000003756 stirring Methods 0.000 description 22
- 230000001476 alcoholic effect Effects 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 10
- 208000035126 Facies Diseases 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229920000768 polyamine Polymers 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical class BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 238000013019 agitation Methods 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000004519 grease Substances 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- BXXWFOGWXLJPPA-UHFFFAOYSA-N 2,3-dibromobutane Chemical compound CC(Br)C(C)Br BXXWFOGWXLJPPA-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- JVIVXEZCSFYOST-UHFFFAOYSA-N C[I](C(c1ccccc11)=O)(C1=O)=C Chemical compound C[I](C(c1ccccc11)=O)(C1=O)=C JVIVXEZCSFYOST-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- GMIAFOQPLJDIFF-UHFFFAOYSA-N Cc(cccc1C(N2)O)c1C2=O Chemical compound Cc(cccc1C(N2)O)c1C2=O GMIAFOQPLJDIFF-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于药物化学领域,具体涉及一种氨基酸-胺缀合物及其制备方法和应用。该氨基酸-胺缀合物具有如下通式:
Description
技术领域
本发明属于药物化学领域,具体涉及一种氨基酸-胺缀合物及其制备方法和应用。
背景技术
多胺广泛存在于原核及真核细胞中,是维持细胞生长的重要物质。多胺的靶向给药能力逐渐引起人们的注意,研究发现人工合成的多胺衍生物可以作为多胺生物合成的抑制剂,作为潜在的细胞生长抑制剂和抗肿瘤药物。药物分子对病变细胞缺乏选择性是癌症化学疗法的主要缺陷之一。随着肿瘤病理学研究的深入,抗肿瘤细胞作用的新靶点—小分子多胺也具有良好的靶向给药能力。
氨基酸是一类广泛存在于自然界中的小分子化合物,其结构上含有氨基和羧基。近年来的深入研究,人们发现很多蛋白氨基酸却有着独特的生物学功能,如参与激素、抗生素等含氮物质的合成等,有些还具有一定的抗癌、抗菌、抗结核、护肝、降血压、升血压的作用,例如谷氨酸、精氨酸、天门冬氨酸、胱氨酸等氨基酸可以单独作用治疗一些疾病,主要用于治疗肝病疾病、消化道疾病、脑病、心血管病、呼吸道疾病以及用于提高肌肉活力、儿科营养和解毒等。
因此,根据多胺、氨基酸的作用特点,设计合成一类氨基酸-胺缀合物,希望达到靶向给药目的,从而实现抗肿瘤的靶向作用。
发明内容
本发明的目的在于提供一种靶向性抗肿瘤的氨基酸-胺缀合物及其制备方法和应用。
本发明采用以下技术方案:
一种氨基酸-胺缀合物,具有如下通式:
其中n=1或2,R为氨基酸残基。
氨基酸-胺缀合物的制备方法,包括以下步骤:
(1)将邻苯二甲酰亚胺()溶于无水乙醇中,加入氢氧化钾(KOH)反应,干燥得固体邻苯二甲酰亚胺钾盐()a;
(2)然后以邻苯二甲酰亚胺钾盐a和二溴代烷烃()为原料,在有机溶剂中反应,经过减压蒸馏和重结晶得到化合物b;
(3)以氨基酸(含多个氨基的氨基酸)为原料,加入二碳酸二叔丁酯反应,用二碳酸二叔丁酯对氨基酸上的a氨基进行保护,经过萃取得到氨基保护的氨基酸化合物c;
(4)将反应所得的化合物c溶于水中,在碱性物质作用下,与所得的化合物b反应,经分离提纯得到化合物d;
(5)将得到的化合物d溶于甲醇中,与二碳酸二叔丁酯((BOC)2O)反应经过萃取得到化合物e;
(6)将得到的化合物e溶于乙醇中,加入水合肼反应,反应结束经过萃取得到化合物f;
(7)将化合物f溶解于乙醇中,加入盐酸反应得到氨基酸-胺缀合物g。
所述步骤(1)中,邻苯二甲酰亚胺和氢氧化钾的摩尔比为1:2-4;
步骤(2)中,有机溶剂是丙酮,反应条件为加热回流,反应时间为12-24h;邻苯二甲酰亚胺钾盐a和二溴代烷烃的摩尔比为1:3-5。
所述步骤(3)中,氨基酸与二碳酸二叔丁酯((BOC)2O)的摩尔比为1:2-4;反应时分别将氨基酸、二碳酸二叔丁酯溶于水、二恶烷中,-5-5℃将二碳酸二叔丁酯的二恶烷溶液加入氨基酸水溶液中,先在-5-1℃反应1-2h,然后升温至20-45℃反应12-24h。
所述步骤(4)中,碱性物质为K2CO3或Na2CO3,碱性物质的用量以调节溶液pH为8-10为准;化合物b和c的摩尔比为1:1-2;反应条件为30-60℃反应12-24h。
所述步骤(5)中,d和二碳酸二叔丁酯的摩尔比为1:1-3;反应条件为20-30℃反应12-24h。
所述步骤(6)中,化合物e和水合肼的摩尔比为1:10-20;反应条件为20-30℃反应12-24h。
所述步骤(7)中,化合物f与盐酸的摩尔比为1:10-20;反应时将化合物f溶于乙醇中,降温至-5-5℃,加入盐酸,然后升温至20-45℃反应12-24h。
氨基酸-胺缀合物在制备靶向性抗肿瘤药物中的应用。
氨基酸-胺缀合物的合成路线如下:
本发明是基于胺的结构,合成了一类氨基酸-胺缀合物。把氨基酸和胺结合在一起,可以改善胺类化合物的水溶性、生物性能和药物靶向性。本发明提供了该氨基酸-胺缀合物的制备方法,该方法具有简单易行、反应操作条件温和、能耗低、投资少、成本低等优点。在抗肿瘤药物的结构中引入氨基酸结构,设计合成新型结构的胺衍生物,制成具有肿瘤靶向性的缀合物,实现抗肿瘤的靶向作用。
附图说明
图1是本发明实施例1修饰化合物g的1HNMR谱。
图2是本发明实施例2修饰化合物g的1HNMR谱。
图3是本发明实施例3修饰化合物g的1HNMR谱。
图4是本发明实施例4修饰化合物g的1HNMR谱。
实验仪器名称与型号:
德国BrukerAV-400型核磁共振仪。
具体实施方式
以下结合实施例对本发明的技术方案进行进一步的说明。
实施例1
制备n=2,R为L-色氨酸残基时,氨基酸-胺缀合物的合成步骤:
1)制备化合物a:在250mL圆底烧瓶中加入7.94g(0.054mol)邻苯二甲酰亚胺()和200mL无水乙醇,加热回流至固体完全溶解,将热溶液倒入含有KOH6.72g(0.12mol)的乙醇溶液中,立即有白色晶体析出,抽滤,干燥得到白色结晶a;
2)制备化合物b:在250mL圆底烧瓶中先后加入97.16g(0.45mol)1,4二溴丁烷和100mL丙酮,搅拌条件下分批加入27.75g(0.15mol)邻苯二甲酰亚胺钾盐a,搅拌回流12h,冷却;过滤除去反应生成的KBr,减压蒸馏除去丙酮和过量的1,4二溴丁烷,剩余固体用无水乙醇重结晶,得到白色固体b;
3)制备化合物c:在100mL圆底烧瓶中加入2.04g(10mmoL)L-色氨酸和10mL水搅拌溶解,冷却至0℃,然后在搅拌条件下缓慢滴加15ml含1.09g(5mmol)(BOC)2O的二恶烷溶液,在0℃下反应1h,然后升温至25℃,搅拌反应12h,用二氯甲烷萃取3次,将水相溶液减压蒸除溶剂水,得淡黄色粘稠状化合物c;
4)制备化合物d:取0.61g(2mmol)化合物c溶于2mL水中,加入0.28g(2mmol)无水K2CO3,室温搅拌15min,然后升温至45℃,慢慢加入0.56g(2mmol)b,控温45℃反应12h,用二氯甲烷或氯仿萃取3次,收集有机相用Na2SO4干燥,将有机相溶液减压蒸除溶剂,得淡黄色粘稠状固体d;
5)制备化合物e:取1.01g(2mmol)化合物d溶于20mL乙醇溶液中,慢慢加入含0.44g(2mmol)(BOC)2O的二恶烷溶液,25℃反应12h,用二氯甲烷或氯仿萃取3次,收集有机相用Na2SO4干燥,将有机相溶液减压蒸除溶剂,干燥得淡黄色粘稠状固体e;
6)制备化合物f:取1.21g(2mmol)化合物e溶于20mL乙醇溶液中,然后加入20mmol的水合肼,室温25℃搅拌12h至有白色不溶固体出现,减压蒸馏除去溶剂,用氯仿萃取3次,将有机相溶液减压蒸除溶剂,得橙黄色油状物固体化合物f;
7)制备化合物g:取0.75g(2mmol)化合物f溶于20mL乙醇溶液中,冷却至0℃,加入5mL4M盐酸的乙醇溶液,升温至25℃,搅拌反应12h至有大量固体生成,蒸出溶剂,干燥,得淡黄色固体化合物g。
如图1所示,是实施例1产品g的1HNMR图谱,实验数据如下:
C15H21N3O2,产率62.3%,淡黄色固体。1HNMR(D2O,400MHz):1.01-1.03(t,2H),1.42-1.49(m,2H),1.53-1.59(m,2H)2.84-2.88(t,2H),3.18-3.28(m,2H),3.56-3.49(m,2H),4.15-4.18(t,1H),7.02-7.06(t,1H),7.10-7.14(t,1H),7.17(s,1H),7.36-7.38(d,1H),7.47-7.49(d,1H)。
实施例2
制备n=2,R为L-半胱氨酸残基时,氨基酸-胺缀合物的合成步骤:
1)制备化合物a:在250mL圆底烧瓶中加入7.94g(0.054mol)邻苯二甲酰亚胺()和200mL无水乙醇,加热回流至固体完全溶解,将热溶液倒入含有KOH6.72g(0.12mol)的乙醇溶液中,立即有白色晶体析出,抽滤,干燥得到白色结晶a;
2)制备化合物b:在250mL圆底烧瓶中先后加入97.16g(0.45mol)1,4二溴丁烷和100mL丙酮,搅拌条件下分批加入16.66g(0.09mol)邻苯二甲酰亚胺钾盐a,搅拌回流24h,冷却,过滤除去反应生成的KBr,减压蒸馏除去丙酮和过量的1,4二溴丁烷,剩余固体用无水乙醇重结晶,得到白色固体b;
3)制备化合物c:在100mL圆底烧瓶中加入2.42g(10mmoL)L-半胱氨酸和10mL水搅拌溶解,冷却至0℃,然后在搅拌条件下缓慢滴加15ml含0.55g(2.5mmol)(BOC)2O的二恶烷溶液,在-5℃下反应2h,然后升温至45℃,搅拌反应24h。用二氯甲烷萃取3次,将水相溶液减压蒸除溶剂水,得淡黄色粘稠状化合物c;
4)制备化合物d:取0.44g(2mmol)化合物c溶于2mL水中,加入0.28g(2mmol)无水K2CO3,室温搅拌15min,然后升温至30℃,慢慢加入0.28g(1mmol)b,控温30℃反应24h,用二氯甲烷或氯仿萃取3次,收集有机相用Na2SO4干燥,将有机相溶液减压蒸除溶剂,得淡黄色粘稠状固体d;
5)制备化合物e:取0.84g(2mmol)化合物d溶于20mL乙醇溶液中,慢慢加入含0.88g(4mmol)(BOC)2O的二恶烷溶液,30℃反应24h,用二氯甲烷或氯仿萃取3次,收集有机相用Na2SO4干燥,将有机相溶液减压蒸除溶剂,干燥得淡黄色粘稠状固体e;
6)制备化合物f:取1.04g(2mmol)化合物e于20mL乙醇溶液中,然后加入40mmol的水合肼,30℃搅拌24h至有白色不溶固体出现,减压蒸馏除去溶剂,用氯仿萃取3次,将有机相溶液减压蒸除溶剂,得橙黄色油状物固体化合物f;
7)制备化合物g:取0.58g(2mmol)化合物f溶于20mL乙醇溶液中,冷却至-5℃,加入5mL4M盐酸的乙醇溶液,升温至45℃,搅拌反应24h至有大量固体生成,蒸出溶剂,干燥,得淡黄色固体化合物g。
如图2所示,是实施例2产品g的1HNMR图谱,实验数据如下:
C7H16N2O2S,产率68.6%,淡黄色固体。1HNMR(D2O,400MHz):1.51-1.67(m,6H),1.96(s,1H),2.52-2.55(t,1H),2.92-2.96(m,2H),3.26(s,1H),3.53-3.56,(t,2H)。
实施例3
制备n=2,R为L-赖氨酸残基时,氨基酸-胺缀合物的合成步骤:
1)制备化合物a:在250mL圆底烧瓶中加入7.94g(0.054mol)邻苯二甲酰亚胺()和200mL无水乙醇,加热回流至固体完全溶解,将热溶液倒入含有KOH6.72g(0.12mol)的乙醇溶液中,立即有白色晶体析出,抽滤,干燥得到白色结晶a;
2)制备化合物b:在250mL圆底烧瓶中先后加入97.16g(0.45mol)1,4二溴丁烷和100mL丙酮,搅拌条件下分批加入27.75g(0.15mol)邻苯二甲酰亚胺钾盐a,搅拌回流20h,冷却。过滤出去反应生成的KBr,减压蒸馏除去丙酮和过量的1,4二溴丁烷,剩余固体用无水乙醇重结晶,得到白色固体b;
3)制备化合物c:在100mL圆底烧瓶中加入1.46g(10mmoL)L-赖氨酸和10mL水搅拌溶解,然后在搅拌条件下缓慢滴加15ml含1.09g(5mmol)(BOC)2O的二恶烷溶液。在0℃下反应1h,然后升温至25℃,搅拌反应12h。用二氯甲烷萃取3次,将水相溶液减压蒸除溶剂水,得淡黄色粘稠状化合物c;
4)制备化合物d:取0.49g(2mmol)化合物c溶于2mL水中,加入0.28g(2mmol)无水K2CO3,室温搅拌15min,然后升温至60℃,慢慢加入0.56g(2mmol)b,控温60℃反应15h,用二氯甲烷或氯仿萃取3次,收集有机相用Na2SO4干燥,将有机相溶液减压蒸除溶剂,得淡黄色粘稠状固体d;
5)制备化合物e:取0.89g(2mmol)化合物d溶于20mL甲醇溶液中,加入含0.44g(2mmol)(BOC)2O,室温25°C搅拌12h,减压蒸馏除去溶剂,用氯仿萃取3次,收集有机相用Na2SO4干燥,减压蒸馏除去溶剂氯仿,得淡黄色固体e;
6)制备化合物f:取1.09g(2mmol)化合物e溶于20mL乙醇溶液中,然后加入40mmol的水合肼,室温25°C搅拌12h至有白色不溶固体出现,减压蒸馏除去溶剂,用氯仿萃取3次,将有机相溶液减压蒸除溶剂,得橙黄色油状物固体化合物f;
7)制备化合物g:取0.83g(2mmol)化合物f溶于20mL乙醇溶液中,冷却至5℃,加入5mL4M盐酸的乙醇溶液,升温至25℃,搅拌反应12h至有大量固体生成,蒸出溶剂,干燥,得淡黄色固体化合物g。
如图3所示,是实施例3产品g的1HNMR图谱,实验数据如下:
C10H23N3O2,产率58.3%,淡黄色固体。1HNMR(D2O,400MHz):1.25-1.29(t,6H),1.54-1.71(m,4H),2.94-3.02(m,2H),3.26-3.27(m,4H),3.56-3.59(t,1H)。
实施例4
制备n=2,R为L-精氨酸残基时,氨基酸-胺缀合物的合成步骤:
1)制备化合物a:在250mL圆底烧瓶中加入7.94g(0.054mol)邻苯二甲酰亚胺()和200mL无水乙醇,加热回流至固体完全溶解,将热溶液倒入含有KOH6.72g(0.12mol)的乙醇溶液中,立即有白色晶体析出,抽滤,干燥得到白色结晶a;
2)制备化合物b:在250mL圆底烧瓶中先后加入97.16g(0.45mol)1,4二溴丁烷和100mL丙酮,搅拌条件下分批加入27.75g(0.15mol)邻苯二甲酰亚胺钾盐a,搅拌回流12h,冷却。过滤出去反应生成的KBr,减压蒸馏除去丙酮和过量的1,4二溴丁烷,剩余固体用无水乙醇重结晶,得到白色固体b;
3)制备化合物c:在100mL圆底烧瓶中加入1.74g(10mmoL)L-精氨酸和10mL水搅拌溶解,冷却至0℃,然后在搅拌条件下缓慢滴加15ml含1.09g(5mmol)(BOC)2O的二恶烷溶液。在0℃下反应1h,然后升温至25℃,搅拌反应12h。用二氯甲烷萃取3次,将水相溶液减压蒸除溶剂水,得淡黄色粘稠状化合物c;
4)制备化合物d:取0.55g(2mmol)化合物c溶于2mL水中,加入0.28g(2mmol)无水K2CO3,室温搅拌15min,然后升温至45℃,慢慢加入0.56g(2mmol)b,控温45℃反应12h,用二氯甲烷或氯仿萃取3次,收集有机相用Na2SO4干燥,将有机相溶液减压蒸除溶剂,得淡黄色粘稠状固体d;
5)制备化合物e:取0.95g(2mmol)化合物d溶于20mL甲醇溶液中,加入含0.44g(2mmol)(BOC)2O,室温25°C搅拌12h,减压蒸馏除去溶剂,用氯仿萃取3次,收集有机相用Na2SO4干燥,减压蒸馏除去溶剂氯仿,得淡黄色固体e;
6)制备化合物f:取1.15g(2mmol)化合物e溶于20mL乙醇溶液中,然后加入20mmol的水合肼,室温25°C搅拌12h至有白色不溶固体出现,减压蒸馏除去溶剂,用氯仿萃取3次,将有机相溶液减压蒸除溶剂,得橙黄色油状物固体化合物f;
7)制备化合物g:取0.89g(2mmol)化合物f溶于20mL乙醇溶液中,冷却至0℃,加入5mL4M盐酸的乙醇溶液,升温至25℃,搅拌反应12h至有大量固体生成,蒸出溶剂,干燥,得淡黄色固体化合物g。
如图4所示,是实施例4产品g的1HNMR图谱,实验数据如下:
C10H23N5O2,产率46.2%,淡黄色固体。1HNMR(D2O,400MHz):1.27-1.30(m,6H),1.62-1.79(m,2H),2.92-2.95(t,1H),3.21-3.34(m,6H)。
应用实验:
细胞培养:HepG2,HeLa,K562和QSG-7701细胞用含10%(v/v)胎牛血清(FBS)的1640培养基于培养瓶中培养,其中含有1%(v/v)的双抗,置于37℃,含5%CO2且湿度为90%的培养箱中孵育。
细胞毒性测试:氨基酸-胺缀合物在HepG2,HeLa,K562和QSG-7701细胞中的细胞毒性采用MTT法测定,用M200酶标仪测定OD值,波长设置为570nm和690nm双波长。没有加入样品的孔的细胞存活率作为对照,设为100%,计算细胞存活率,同时作图并求得半数杀伤浓度(IC50),评价样品的细胞毒性。结果见表一。
表一氨基酸-胺缀合物的细胞毒性
表1中测试了氨基酸-胺缀合物对HepG2、K562和QSG-7701细胞的体外生长抑制活性,实验结果表明该氨基酸-胺缀合物则具有较强的抗肿瘤活性,在肿瘤细胞上的表达效率提高,且肿瘤靶向性的作用比较明显,表现在对正常细胞的细胞毒性比较低。综上,本发明中的氨基酸-胺缀合物可以作为靶向性抗肿瘤药物使用。采用本发明方法制备的氨基酸-胺缀合物,为未见文献报道的新化合物,该氨基酸-胺缀合物具有如下用途:作为靶向性抗肿瘤药物使用,标记肿瘤细胞。
Claims (9)
1.一种氨基酸-胺缀合物,其特征在于,结构式分别为、、,其中n=1或2。
2.权利要求1所述的氨基酸-胺缀合物的制备方法,其特征在于包括以下步骤:
(1)将邻苯二甲酰亚胺溶于无水乙醇中,加入氢氧化钾反应,干燥得固体邻苯二甲酰亚胺钾盐a;
(2)然后以邻苯二甲酰亚胺钾盐a和二溴代烷烃为原料,在有机溶剂中反应,经过减压蒸馏和重结晶得到化合物b;
(3)以氨基酸为原料,加入二碳酸二叔丁酯反应,经过萃取得到氨基保护的氨基酸化合物c;
(4)将反应所得的化合物c溶于水中,在碱性物质作用下,与所得的化合物b反应,经分离提纯得到化合物d;
(5)将得到的化合物d溶于甲醇中,与二碳酸二叔丁酯反应经过萃取得到化合物e;
(6)将得到的化合物e溶于乙醇中,加入水合肼反应,反应结束经过萃取得到化合物f;
(7)将化合物f溶解于乙醇中,加入盐酸反应得到氨基酸-胺缀合物g。
3.如权利要求2所述的氨基酸-胺缀合物的制备方法,其特征在于,步骤(1)中,邻苯二甲酰亚胺和氢氧化钾的摩尔比为1:2-4;步骤(2)中,有机溶剂是丙酮,反应条件为加热回流,反应时间为12-24h,邻苯二甲酰亚胺钾盐a和二溴代烷烃的摩尔比为1:3-5。
4.如权利要求2所述的氨基酸-胺缀合物的制备方法,其特征在于,步骤(3)中,氨基酸与二碳酸二叔丁酯的摩尔比为1:2-4;反应条件为先在-5-1℃反应1-2h,然后升温至20-45℃反应12-24h。
5.如权利要求2所述的氨基酸-胺缀合物的制备方法,其特征在于,步骤(4)中,碱性物质为K2CO3或Na2CO3,碱性物质的用量以调节溶液pH为8-10为准;化合物b和c的摩尔比为1:1-2;反应条件为30-60℃反应12-24h。
6.如权利要求2所述的氨基酸-胺缀合物的制备方法,其特征在于,步骤(5)中,化合物d和二碳酸二叔丁酯的摩尔比为1:1-3;反应条件为20-30℃反应12-24h。
7.如权利要求2所述的氨基酸-胺缀合物的制备方法,其特征在于,步骤(6)中,化合物e和水合肼的摩尔比为1:10-20;反应条件为20-30℃反应12-24h。
8.如权利要求2所述的氨基酸-胺缀合物的制备方法,其特征在于,步骤(7)中,化合物f与盐酸的摩尔比为1:10-20;反应时将化合物f溶于乙醇中,降温至-5-5℃,加入盐酸,然后升温至20-45℃反应12-24h。
9.权利要求1所述的氨基酸-胺缀合物在制备靶向性抗肿瘤药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410074636.0A CN103833623B (zh) | 2014-03-03 | 2014-03-03 | 一种氨基酸-胺缀合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410074636.0A CN103833623B (zh) | 2014-03-03 | 2014-03-03 | 一种氨基酸-胺缀合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103833623A CN103833623A (zh) | 2014-06-04 |
CN103833623B true CN103833623B (zh) | 2016-07-06 |
Family
ID=50797564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410074636.0A Expired - Fee Related CN103833623B (zh) | 2014-03-03 | 2014-03-03 | 一种氨基酸-胺缀合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103833623B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6495714B2 (ja) * | 2015-03-31 | 2019-04-03 | 国立大学法人 長崎大学 | 新規膜透過性ペプチド |
MX2019002607A (es) * | 2016-09-07 | 2019-09-18 | Univ Temple | Composiciones y metodos para el tratamiento de resistencia a la insulina. |
CN110317153A (zh) * | 2019-06-03 | 2019-10-11 | 吉尔生化(上海)有限公司 | 一种Nα-芴甲氧羰基-N',N''-二甲酸丙烯基-L-精氨酸的制备方法 |
CN113980671B (zh) * | 2021-11-11 | 2024-07-23 | 河南大学 | 多胺衍生物修饰的量子点、制备方法和作为纳米药物载体的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867237B1 (en) * | 2001-07-23 | 2005-03-15 | Senesco Technologies, Inc. | DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans |
US20130197038A1 (en) * | 2012-01-18 | 2013-08-01 | Massachusetts Institute Of Technology | Compositions And Methods For Neovascularization |
CN103435586A (zh) * | 2013-08-06 | 2013-12-11 | 河南大学 | 含黄酮结构的多胺衍生物及其制备方法和应用 |
-
2014
- 2014-03-03 CN CN201410074636.0A patent/CN103833623B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6867237B1 (en) * | 2001-07-23 | 2005-03-15 | Senesco Technologies, Inc. | DNA encoding apoptosis-induced eucaryotic initiation factor-5A and deoxyhypusine synthase and a method for controlling apoptosis in animals and humans |
US20130197038A1 (en) * | 2012-01-18 | 2013-08-01 | Massachusetts Institute Of Technology | Compositions And Methods For Neovascularization |
CN103435586A (zh) * | 2013-08-06 | 2013-12-11 | 河南大学 | 含黄酮结构的多胺衍生物及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
Chromatographic identification of hypusine[N1-(4-amino-2-hydroxybutyl)lysine] and deoxyhypusine [N1-(4-aminobutyl)lysine];MYUNG HEE PARK,等;《Methods in Enzymology》;19831231;第94卷;第458-462页尤其参见第458页 * |
The biosynthesis of protein-bound hypusine[Nε-(4-amino-2-hydroxybutyl)lysine];Myung Hee Park,等;《Journal of Biological Chemistry》;19820625;第257卷(第12期);第7217-7222页,尤其参见第7217页右栏 * |
Also Published As
Publication number | Publication date |
---|---|
CN103833623A (zh) | 2014-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sribalan et al. | Synthesis and biological evaluation of new symmetric curcumin derivatives | |
CN103833623B (zh) | 一种氨基酸-胺缀合物及其制备方法和应用 | |
CN103320118B (zh) | 一种希夫碱铜离子荧光探针及其制备方法 | |
CN113683557B (zh) | 一种茂基铱/铑二聚体的应用 | |
CN102127142A (zh) | 救必应酸衍生物及其在制备抗肿瘤的药物中的应用 | |
CN106866572B (zh) | 一氧化氮供体型β‑榄香烯衍生物及其制备方法和用途 | |
CN115260083A (zh) | 一种线粒体靶向的粘度响应荧光探针的制备方法及应用 | |
CN105503627A (zh) | 一种新型棉酚希夫碱衍生物及其制备方法与应用 | |
CN107445935B (zh) | 一种酰胺基取代的橙皮素类衍生物及其制备和作为抗炎的药物中的应用 | |
CN110563624B (zh) | 具有抑癌活性的2-丙酮基硒基苯甲酰胺类化合物及用途 | |
CN102924372B (zh) | 一种抗肿瘤2-氨基-3-氰基吡啶及其应用、制备方法 | |
CN106928293A (zh) | 一类具有抗肿瘤活性的呋咱no供体型灯盏乙素衍生物及其制备方法和用途 | |
CN102875462B (zh) | 一种抗肿瘤2-氨基烟腈及其应用、制备方法 | |
CN108690033B (zh) | 含黄酮类药物活性分子的荧光探针及其制备方法和应用 | |
CN107501303B (zh) | 一种布洛芬与喹啉-8-甲醛席夫碱构筑的铜(ii)配合物及其合成方法和应用 | |
CN103254143B (zh) | 4-[4-(2-二乙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用 | |
CN103012394B (zh) | 一种罗丹宁衍生物及其制备方法 | |
CN102491934B (zh) | 羟基苯甲醛吲哚席夫碱及其制备方法和应用 | |
CN103787902B (zh) | 苄基取代的苯胺类化合物及其应用 | |
CN103435586B (zh) | 含黄酮结构的多胺衍生物及其制备方法和应用 | |
CN101967163B (zh) | 对癌细胞有选择性的铂(ⅱ)抗癌配合物 | |
CN104910074A (zh) | 一类含有羟肟酸基团的吡唑类衍生物及其制备方法及用途 | |
CN109369634B (zh) | 具有抗肿瘤活性的2-甲氧基烟酰胺衍生物制备方法及用途 | |
CN102603555A (zh) | 一种全反式维甲酸酰胺衍生物及其制备方法和应用 | |
CN102977081B (zh) | 胡椒乙胺缩吡啶-2-甲醛及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160706 |
|
CF01 | Termination of patent right due to non-payment of annual fee |